Abrocitinib治疗中重度特应性皮炎的III期研究:已达到主要终点

2020-11-11 Allan MedSci原创

辉瑞公司今日表示,abrocitinib治疗中度至重度特应性皮炎的12岁及12岁以上患者的III期研究达到了其主要终点。

特应性皮炎是一种慢性、瘙痒性、炎症性皮肤病,最常累及儿童,但也累及许多成人。特应性皮炎的临床特征包括皮肤干燥、红斑、渗出和结痂,以及苔癣样变。瘙痒是此病的标志,并且是给患者及其家人造成疾病负担的主要原因。

辉瑞公司今日表示,abrocitinib治疗中度至重度特应性皮炎的12岁及12岁以上患者的III期研究达到了其主要终点:与安慰剂相比,两种剂量的JAK1抑制剂均可显著减少患者发生耀斑的可能性。

JADE REGIMEN研究对abrocitinib治疗12岁及以上的中度至重度特应性皮炎患者进行了研究,共招募了1233例患者,患者被随机分配接受200 mg或100 mg剂量的安慰剂或abrocitinib。

具体而言,安慰剂组、高剂量abrocitinib组、高剂量转低剂量abrocitinib组在第52周时发生耀斑的可能性分别为81.1%、57.4%和19.1% 。辉瑞补充说,两种剂量的abrocitinib也都达到了主要次要终点。

 

原始出处:

https://www.firstwordpharma.com/node/1773145?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 28 02:44:42 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977030, encodeId=4b3419e7030fb, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jun 12 11:44:42 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Apr 12 14:44:42 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916370, encodeId=332819163e09e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 09 02:44:42 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Dec 12 00:44:42 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594834, encodeId=abad159483464, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 13 14:44:42 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1775, encryptionId=a7381e7586, topicName=abrocitinib), TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:50:17 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 28 02:44:42 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977030, encodeId=4b3419e7030fb, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jun 12 11:44:42 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Apr 12 14:44:42 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916370, encodeId=332819163e09e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 09 02:44:42 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Dec 12 00:44:42 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594834, encodeId=abad159483464, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 13 14:44:42 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1775, encryptionId=a7381e7586, topicName=abrocitinib), TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:50:17 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2021-06-12 linlin2312
  3. [GetPortalCommentsPageByObjectIdResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 28 02:44:42 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977030, encodeId=4b3419e7030fb, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jun 12 11:44:42 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Apr 12 14:44:42 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916370, encodeId=332819163e09e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 09 02:44:42 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Dec 12 00:44:42 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594834, encodeId=abad159483464, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 13 14:44:42 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1775, encryptionId=a7381e7586, topicName=abrocitinib), TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:50:17 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 28 02:44:42 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977030, encodeId=4b3419e7030fb, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jun 12 11:44:42 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Apr 12 14:44:42 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916370, encodeId=332819163e09e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 09 02:44:42 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Dec 12 00:44:42 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594834, encodeId=abad159483464, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 13 14:44:42 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1775, encryptionId=a7381e7586, topicName=abrocitinib), TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:50:17 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2021-01-09 juliusluan78
  5. [GetPortalCommentsPageByObjectIdResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 28 02:44:42 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977030, encodeId=4b3419e7030fb, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jun 12 11:44:42 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Apr 12 14:44:42 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916370, encodeId=332819163e09e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 09 02:44:42 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Dec 12 00:44:42 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594834, encodeId=abad159483464, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 13 14:44:42 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1775, encryptionId=a7381e7586, topicName=abrocitinib), TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:50:17 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 28 02:44:42 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977030, encodeId=4b3419e7030fb, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jun 12 11:44:42 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Apr 12 14:44:42 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916370, encodeId=332819163e09e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 09 02:44:42 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Dec 12 00:44:42 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594834, encodeId=abad159483464, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 13 14:44:42 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1775, encryptionId=a7381e7586, topicName=abrocitinib), TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:50:17 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2021379, encodeId=33ef20213e978, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Sat Nov 28 02:44:42 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977030, encodeId=4b3419e7030fb, content=<a href='/topic/show?id=b9f11560065' target=_blank style='color:#2F92EE;'>#ROC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15600, encryptionId=b9f11560065, topicName=ROC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d590125, createdName=linlin2312, createdTime=Sat Jun 12 11:44:42 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996980, encodeId=188019969804f, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Mon Apr 12 14:44:42 CST 2021, time=2021-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916370, encodeId=332819163e09e, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Jan 09 02:44:42 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Sat Dec 12 00:44:42 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594834, encodeId=abad159483464, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Nov 13 14:44:42 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1775, encryptionId=a7381e7586, topicName=abrocitinib), TopicDto(id=10237, encryptionId=35791023eaf, topicName=JAK抑制剂), TopicDto(id=103769, encryptionId=f12a103e6970, topicName=特异性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Nov 12 09:50:17 CST 2020, time=2020-11-12, status=1, ipAttribution=)]
    2020-11-12 lovetcm

    #abrocitinib#作为#JAK抑制剂#也会成为#特异性皮炎#治疗的选择,未来会与单抗,PDE-5抑制剂等形成竞争,使得治疗多样化,医生的选择也会增加

    0

相关资讯

J Allergy Clin Immunol:尼莫利珠单抗可快速持续改善特应性皮炎患者的皮肤炎症和瘙痒症状

尼莫利珠单抗靶向特应性皮炎(AD)中的IL-31受体α亚单位。本研究旨在评估奈莫利珠单抗在AD患者中的新用药策略。

Clin Oral Investig:研究揭示CHI3L1在特应性皮炎发生和进展中的作用

特应性皮炎(AD)是一种以皮肤屏障缺陷和Th2免疫反应为特征的慢性炎症性皮肤病。壳蛋白酶3-样 1(CHI3L1),在小鼠中也被称为乳腺回归蛋白39(BRP-39)和人类同源物YKL-40,在Th2炎

国家药监局批准非激素外用PDE4抑制剂舒坦明(克立硼罗)用于特应性皮炎治疗

辉瑞(Pfizer)近日宣布,中国国家药品监督管理局(NMPA)已正式批准舒坦明(克立硼罗)2%软膏剂的进口药品注册证。舒坦明在中国被批准用于2岁及以上轻度至中度特应性皮炎(AD)患者的局部外用治疗。

J Invest Dermatol:Dupilumab对IL-4Rα的阻断作用可降低特应性皮炎患者皮肤上金葡菌的定植并增加微生物的多样性

Dupilumab是一种白细胞介素-4受体α的全人抗体,可改善中度至重度特应性皮炎(AD)的症状和体征。一项双盲、安慰剂对照研究旨在确定杜匹鲁单抗对皮肤上金黄色葡萄球菌定植和微生物多样性的

J Am Acad Dermatol:杜匹鲁单抗可有效治疗特应性皮炎

中度至重度特应性皮炎(AD)的长期治疗存在巨大的需求缺口。本研究旨在评估杜比卢单抗在AD患者中的长期安全性和有效性。

儿童顽固“湿疹”可能是特应性皮炎 非激素用药正式上市

据统计,在我国约有7000-9000万特应性皮炎患者,其中中重度患者占到了30%,由剧烈瘙痒引起的睡眠缺失及心理问题严重影响着患者生活质量,同时也给患者家庭和社会带来巨大的经济负担。

拓展阅读

阿布昔替尼片青少年新适应症获批,为中国12岁及以上青少年AD患者带来“突破性疗法”

此次扩年龄新适应症的获批将为青少年特应性皮炎患者带来全新的治疗选择,为疾病长期控制带来全新治疗方案。

Front Pharmacol:防己地黄汤通过IL-17信号通路改善DNCB诱导的特应性皮炎样皮损,整合网络分析与实验验证

FJDHF可能通过抑制IL-17信号通路抑制DNCB诱导的小鼠AD样皮肤炎症。因此,FJDHF可以被认为是一种潜在的AD治疗剂。

黑科技:肉毒毒素注射治疗特应性皮炎

本研究试图通过比较治疗前后的SCORAD值来评估BTX-A在慢性、轻度和中度至重度AD患者中的结果,并检测治疗后SCORAD的变化数量。

J Ethnopharmacol:加味过敏煎通过HIS/PAR-2通路调节特应性皮炎小鼠肥大细胞脱颗粒

探讨加味过敏煎(JWGMD)对2,4-二硝基氟苯(DNFB)诱导的特应性皮炎(AD)小鼠肥大细胞脱颗粒的潜在影响,并研究JWGMD缓解疾病进展的有效性,进一步为治疗AD提供特异性的治疗靶点。

JAMA Dermatol:揭示JAK抑制剂:炎症性皮肤病中心血管和血栓风险的隐藏真相

在这项系统综述和荟萃分析中,与安慰剂/活性药物对照组相比,使用JAK抑制剂与全因死亡率、主要心血管不良事件和静脉血栓栓塞风险增加无关。